Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8671530 | 0.92 | CHRM1 (0.78) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL319049 | 0.90 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL13911140 | 0.89 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL3142425 | 0.87 | CHRM1 (0.81) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL4084782 | 0.87 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL3146496 | 0.85 | CHRM2 (0.83) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL29467164 | 0.84 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL44492 | 0.84 | CHRM1 (0.63) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL342295 | 0.83 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL2255984 | 0.83 | CHRM1 (0.62) | CHRM1CHRM2CHRM4CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
| EP-2822555-A2 | INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN | Lexicon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2822944-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN, INC. (US) | 2015-01-14 | — | — | EP | disclosed |
| WO-2013134079-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013134079-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| EP-2050450-A1 | 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2009-04-22 | — | — | EP | disclosed |
| US-7495109-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2009-02-24 | — | — | US | disclosed |
| US-7495109-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1379246-B1 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2008-10-08 | — | — | EP | disclosed |
| EP-1930322-A1 | 1-(4-piperidinyl)-1,3-dihydro-2H-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and ORL1 ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-06-11 | — | — | EP | disclosed |
| EP-1918279-A2 | 1-(4-piperidinyl)-1,3-dihydro-2h-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and opioid receptor like receptor (ORL1) ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-05-07 | — | — | EP | disclosed |
| US-5691323-A | BENZIMIDAZOL-2-ONES | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1997016187-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5574044-A | BENZIMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF MYOPIA | MERCK & CO., INC. (US) | 1996-11-12 | — | — | US | disclosed |
| WO-1996013262-A1 | MUSCARINE ANTAGONISTS | MERCK & CO., INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | CHRM1 4740/4885CHRM2 4856/4885CHRM4 4833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.